- Title: Subtitle
- Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma
- Creators
- Frederick Lundry Locke - Moffitt Cancer CenterArmin Ghobadi - Washington University in St. LouisLazaros J. Lekakis - University of Miami Health SystemDavid Bernard Miklos - Stanford UniversityCaron A. Jacobson - Dana-Farber Cancer InstituteEric D. Jacobsen - Dana-Farber Cancer InstituteIra Braunschweig - Albert Einstein College of MedicineOlalekan O. Oluwole - Vanderbilt UniversityTanya Siddiqi - City Of Hope National Medical CenterYi Lin - Mayo ClinicPatrick Michael Reagan - University of Rochester Medical CenterUmar Farooq - University of IowaAbhinav Deol - Wayne State UniversityAdrian Bot - Whitney Museum of American ArtJohn M. Rossi - Kite (United States)Yizhou Jiang - Kite (United States)Allen Xue - Whitney Museum of American ArtWilliam Y. Go - Whitney Museum of American ArtSattva Swarup Neelapu - The University of Texas MD Anderson Cancer Center
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.3039-3039
- DOI
- 10.1200/JCO.2018.36.15_suppl.3039
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2018
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984362337402771
Abstract
Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma
Journal of clinical oncology, Vol.36(15_suppl), pp.3039-3039
05/20/2018
DOI: 10.1200/JCO.2018.36.15_suppl.3039
Details
Metrics
19 Record Views